FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma

June 10, 2019 – Today, the U.S. Food and Drug Administration granted accelerated approval to polatuzumab vedotin-piiq, in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse large B-cell lymphoma (DLBCL) that has progressed or returned after at least two prior therapies. Polatuzumab vedotin-piiq is a novel antibody-drug conjugate, and DLBCL is the most common … (leggi tutto)